Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis.

Iyad AlnahhasMouaz AlsawasAppaji RayiJoshua D PalmerRaju RavalShirley OngPierre GiglioMohammad Hassan MuradVinay Puduvalli

Published in: Neuro-oncology advances (2020)

This meta-analysis provides estimates of survival for patients with MGMT methylated or unmethylated GBM treated with RT/TMZ. Further research is needed to delineate whether TMZ should be withheld for patients with unmethylated GBM outside of the setting of clinical trials.

Keyphrases

systematic review
clinical trial
dna methylation
meta analyses
newly diagnosed
transcription factor
randomized controlled trial
phase ii
open label